Research Analysts Offer Predictions for Enanta Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report) – HC Wainwright lifted their Q3 2024 earnings per share estimates for shares of Enanta Pharmaceuticals in a research report issued on Thursday, February 8th. HC Wainwright analyst E. Arce now forecasts that the biotechnology company will earn ($0.91) per share for the quarter, up from their prior estimate of ($0.95). HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.71) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q4 2024 earnings at ($0.72) EPS, FY2024 earnings at ($4.35) EPS, FY2025 earnings at ($6.89) EPS, FY2026 earnings at ($6.49) EPS, FY2027 earnings at ($5.47) EPS and FY2028 earnings at ($5.14) EPS.

A number of other equities research analysts have also recently weighed in on ENTA. JMP Securities dropped their price target on Enanta Pharmaceuticals from $42.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, November 21st. Oppenheimer dropped their price target on Enanta Pharmaceuticals from $25.00 to $21.00 and set a “market perform” rating for the company in a report on Wednesday, November 22nd. StockNews.com downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Finally, JPMorgan Chase & Co. dropped their target price on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $19.33.

View Our Latest Stock Report on ENTA

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $12.33 on Monday. The business has a fifty day moving average price of $10.88 and a 200 day moving average price of $11.65. Enanta Pharmaceuticals has a fifty-two week low of $8.08 and a fifty-two week high of $54.94. The stock has a market capitalization of $260.90 million, a price-to-earnings ratio of -1.88 and a beta of 0.43.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Free Report) last issued its earnings results on Monday, November 20th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.78. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The business had revenue of $18.93 million during the quarter, compared to analysts’ expectations of $17.93 million. During the same period in the prior year, the firm posted ($1.27) EPS.

Insider Buying and Selling

In related news, CEO Jay R. Luly sold 7,230 shares of Enanta Pharmaceuticals stock in a transaction on Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total transaction of $69,624.90. Following the completion of the sale, the chief executive officer now directly owns 806,793 shares of the company’s stock, valued at $7,769,416.59. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 7,230 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $69,624.90. Following the completion of the transaction, the chief executive officer now directly owns 806,793 shares of the company’s stock, valued at $7,769,416.59. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Terry Vance sold 15,295 shares of the business’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $9.12, for a total value of $139,490.40. Following the completion of the transaction, the director now directly owns 5,800 shares of the company’s stock, valued at $52,896. The disclosure for this sale can be found here. Insiders sold a total of 27,596 shares of company stock valued at $257,949 over the last three months. Company insiders own 13.64% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its stake in shares of Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,281 shares in the last quarter. US Bancorp DE grew its stake in shares of Enanta Pharmaceuticals by 353.1% in the fourth quarter. US Bancorp DE now owns 4,187 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 3,263 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Enanta Pharmaceuticals by 80.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,026 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 901 shares in the last quarter. Clearstead Advisors LLC bought a new position in shares of Enanta Pharmaceuticals in the third quarter valued at $57,000. Finally, Royal Bank of Canada grew its stake in shares of Enanta Pharmaceuticals by 68.7% in the second quarter. Royal Bank of Canada now owns 2,665 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,085 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Featured Articles

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.